Biosimilars Market Research and Growth Report, 2014 to 2024

1
Your Catalyst To a Lucrative Business
Biosimilars Market Share, Size, Analysis, Growth,
Trends and Forecasts to 2024 Hexa Research
Biosimilars Market Size Expected To Reach
USD 13.1 Billion By 2024
The global Biosimilars Market is expected to
reach USD 13.1 billion by 2024 on account of
increase in the prevalence of chronic diseases
such as cancer, diabetics, cardiac disorders and
autoimmune diseases. Rising demand for the
cost-effective therapies is expected to drive the
market in the forecast period. Biosimilars are
about 30 cheaper than their counterpart
biologics. Furthermore, the patent expiry of the
blockbuster drugs is anticipated to provide a
lucrative opportunity for the growth of
biosimilars. For instance, a patent for
Bevacizumab, sold under the trade name Avastin is
expiring in 2019.
Moreover, increasing government initiatives,
speedy drug approvals and reimbursement policies
are expected to boost the market for the
biosimilars in the study period. Also, market
giants are adopting merger acquisition
strategies to increase their product portfolio.
For instance, in 2015, Pfizer, Inc. acquired
Hospira, a key player in biosimilars market.
Browse Details of Report _at_ https//www.hexaresearc
h.com/research-report/biosimilars-market
Follow Us
2
Your Catalyst To a Lucrative Business
In 2016, oncology was the largest segment,
accounting for 32 market share. Increasing
prevalence of cancer across the globe is the key
factor driving the growth of the market over the
forecast period. For instance, according to the
American Cancer Society, an estimated 1.6 lakh
people suffered from cancer in 2016. Also,
increasing government initiatives to provide cost
effective treatment to cure deadly diseases will
boost the penetration of biosimilar in developing
countries which in turn will increase the market
for biosimilar over the forecast period. For
instance, WHO launched a pilot program for
prequalifying biosimilar drug, making some of the
most expensive treatments for cancer more widely
available in developing countries. Under this
initiative, WHO has focused on two essential drug
rituximab (principally used for the treatment of
non- Hodgkin's lymphoma and chronic lymphocytic
leukaemia), and trastuzumab (for the treatment of
breast cancer).
In terms of region, Europe dominates the market
for biosimilars followed by North America. The
dominance of Europe is due speedy approval of the
drug by European regulatory bodies. Furthermore,
improving healthcare infrastructure and ageing
population is expected to drive the market over
the forecast period. However, Asia Pacific is
projected to be the fastest growing region owing
to the increasing disposable income of
middle-class families, growing medical tourism
and improving healthcare infrastructure.
Furthermore, increasing investment in RD
activities by pharmaceutical giants is expected
to boost the market in the projected period.
Hexa Research has segmented the global
biosimilars market based on indication and region
Segmentation by indication, 2014 - 2024 (USD
Million) Blood Disorders Oncology Chronic
Autoimmune Diseases Others
Segmentation by region, 2014 - 2024 (USD
Million) North America U.S.
Europe
Germany Asia Pacific China India
Japan Rest of the world
Key players analyzed Dr. Reddys Laboratories
Ltd
Follow Us
3
Your Catalyst To a Lucrative Business
Mylan
Shanghai Fosun Pharmaceutical (Group) Co.,
Ltd. Pfizer Inc. Sandoz International GmbH
Teva Pharmaceuticals Industries Ltd. Amgen
Inc. STADA Arzneimittel AG Biocon
F. Hoffmann-La Roche Ltd.
Browse Related Category Market Reports _at_
https//www.hexaresearch.com/research-category/hea
lthcare-industry
Follow Us
4
Your Catalyst To a Lucrative Business
Table of Contents
Chapter 1. Market Summary
1.1. Market trends movement Chapter 2. Global
Biosimilars Market Trends Drivers
Opportunities 2.1. Introduction
2.2. Key industry trends 2.3. Market drivers 2.4.
Market restraints 2.5. Value chain analysis 2.6.
Porter's Five Forces analysis 2.7. SWOT
Chapter 3. Global Biosimilars Market Trends, By
Indication 3.1. Global Biosimilars market
movement, by indication, 2016 2024 3.1.1. Blood
disorders
3.1.1.1. Market estimates and forecast, 2014 -
2024 (USD Million) 3.1.2. Oncology 3.1.2.1.
Market estimates and forecast, 2014 - 2024 (USD
Million) 3.1.3. Chronic Autoimmune
Diseases 3.1.3.1. Market estimates and forecast,
2014 - 2024 (USD Million) 3.1.4. Others
3.1.4.1. Market estimates and forecast, 2014 -
2024 (USD Million) Chapter 4. Global Automotive
Suspension Market Trends, By Region 4.1. Global
automotive suspension market movement, by region,
2016 2024 4.1.1. North America
4.1.1.1. Market estimates and forecast, 2014 -
2024 (USD Million) 4.1.1.2. Market estimates and
forecast, by indication, 2014 - 2024 (USD
Million) 4.1.2. Europe 4.1.2.1. Market estimates
and forecast, 2014 - 2024 (USD Million) 4.1.2.2.
Market estimates and forecast, by indication,
2014 - 2024 (USD Million) 4.1.3. Asia
Pacific 4.1.3.1. Market estimates and forecast,
2014 - 2024 (USD Million) 4.1.3.2. Market
estimates and forecast, by indication, 2014 -
2024 (USD Million) 4.1.4. Rest of the World
4.1.4.1. Market estimates and forecast, 2014 -
2024 (USD Million) 4.1.4.2. Market estimates and
forecast, by indication, 2014 - 2024 (USD
Million) Chapter 5. Competitive Landscape
5.1. Competitive landscape analysis, 2016 5.2.
Strategic framework 5.3. Potential customer base
concentration 5.4. Company market positioning
5.5. Company profiles
Follow Us
5
Your Catalyst To a Lucrative Business
5.5.1. Dr. Reddys Laboratories Ltd.
5.5.1.1. Company Overview 5.5.1.2. Product
Benchmarking 5.5.1.3. Financial
Performance 5.5.1.4. Recent Initiatives
5.5.2. Mylan
5.5.2.1. Company Overview 5.5.2.2. Product
Benchmarking 5.5.2.3. Financial
Performance 5.5.2.4. Recent Initiatives 5.5.3.
Shanghai Fosun Pharmaceutical (Group) Co.,
Ltd. 5.5.3.1. Company Overview 5.5.3.2. Product
Benchmarking 5.5.3.3. Financial
Performance 5.5.3.4. Recent Initiatives
5.5.4. Pfizer Inc.
5.5.4.1. Company Overview 5.5.4.2. Product
Benchmarking 5.5.4.3. Financial
Performance 5.5.4.4. Recent Initiatives 5.5.5.
Sandoz International GmbH 5.5.5.1. Company
Overview 5.5.5.2. Product Benchmarking 5.5.5.3.
Financial Performance 5.5.5.4. Recent
Initiatives 5.5.6. Teva Pharmaceuticals
Industries Ltd. 5.5.6.1. Company
Overview 5.5.6.2. Product Benchmarking 5.5.6.3.
Financial Performance 5.5.6.4. Recent Initiatives
5.5.7. Amgen Inc.
5.5.7.1. Company Overview 5.5.7.2. Product
Benchmarking 5.5.7.3. Financial
Performance 5.5.7.4. Recent Initiatives 5.5.8.
STADA Arzneimittel AG 5.5.8.1. Company
Overview 5.5.8.2. Product Benchmarking 5.5.8.3.
Financial Performance 5.5.8.4. Recent Initiatives
5.5.9. Biocon 5.5.9.1. Company Overview
Follow Us
6
Your Catalyst To a Lucrative Business
5.5.9.2. Product Benchmarking 5.5.9.3. Financial
Performance 5.5.9.4. Recent Initiatives 5.5.10.
F. Hoffmann-La Roche Ltd. 5.5.10.1. Company
Overview 5.5.10.2. Product Benchmarking 5.5.10.3.
Financial Performance 5.5.10.4. Recent Initiatives
5.5.11. List of other vendors
Chapter 6. Methodology and Scope
6.1. Research methodology 6.2. Research Scope
Assumptions 6.3. List of data sources
Follow Us
7
Your Catalyst To a Lucrative Business
About Us
Hexa Research is a market research and consulting
organization, offering industry reports, custom
research and consulting services to a host of key
industries across the globe. We offer
comprehensive business intelligence in the form
of industry reports which help our clients obtain
clarity about their business environment and
enable them to undertake strategic growth
initiatives.
Contact Us
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018 United States
Phone [phone] Email sales_at_hexaresearch.c
om Website - https//www.hexaresearch.com/
Follow Us